Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral Sleeping Beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma

Chaopin Yang,Jinqi You,Qiuzhong Pan,Yan Tang,Liming Cai,Yue Huang,Jiamei Gu,Yizhi Wang,Xinyi Yang,Yufei Du,Dijun Ouyang,Hao Chen,Haoran Zhong,Yongqiang Li,Jieying Yang,Yulong Han,Fengze Sun,Yuanyuan Chen,Qijing Wang,Desheng Weng,Zhongqiu Liu,Tong Xiang,Jianchuan Xia

DOI: https://doi.org/10.1186/s12916-023-03016-0

IF: 9.3

2023-08-30

BMC Medicine

Abstract:CD133 is considered a marker for cancer stem cells (CSCs) in several types of tumours, including hepatocellular carcinoma (HCC). Chimeric antigen receptor-specific T (CAR-T) cells targeting CD133-positive CSCs have emerged as a tool for the clinical treatment of HCC, but immunogenicity, the high cost of clinical-grade recombinant viral vectors and potential insertional mutagenesis limit their clinical application.

medicine, general & internal